Tuesday, 18 Feb 2020

You are here

Febuxostat (IR or XR) Effective in Gout with Renal Impairment

Saag and colleagues report the results of a 3 month phase III trial demonstrating equal efficacy between febuxostat extended release (XR) and immediate release (IR) formulations in patients with gout.  and normal or impaired renal function.

This multicenter, placebo-controlled, double-blind study enrolled 1790 gout patients with normal or impaired (mild to severe) renal function and randomized them to receive placebo, febuxostat IR 40 or 80 mg, or febuxostat XR 40 or 80 mg once daily (1:1:1:1:1 ratio).

Febuxostat in either formulation was significantly better at achieving sUA <5.0 mg/dL or sUA <6.0 mg/dL at Month 3 (P<0.001 versus placebo).

While both febuxostat XR and IR had similar effects on sUA endpoints, significantly more patients achieved sUA <5.0 mg/dL with XR 40 mg versus IR 40 mg.

Flare rates were similar across all treatment groups and no new or extraordinary safety concerns were raised by these studies. Adverse events were low in frequency and lead by  diarrhea, nasopharyngitis, and hypertension.

Both febuxostat formulations were well tolerated and equally effective (sUA) in patients with normal and impaired renal function. These data do add to the growing body of evidence supporting the use of febuxostat in the management of hyperuricemia in patients with renal impairment.  

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Hypersensitivity Reactions and Gout Tx: Watch the Dose

Both allopurinol and febuxostat (Uloric) were associated with an increased risk of hypersensitivity reactions among new users of these urate-lowering therapies, a large U.S. study found.

Diabetics using SGLT2 Inhibitors have a lower Gout Risk

Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes mellitus (T2DM).

A Role for SGLT2 Inhibition in Gout?

The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.

Predicting Inpatient Gout Flares

Analysis of New Zealand hospitalized patients revals nine predictors of inpatient flare for people with comorbid gout.

This retrospective cohort study of hospitalised patients with comorbid gout included 625 hospitalised patients, 87 experienced inpatient gout flare.

There were 9 predictors of an inpatient gout flare:

Pegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout

Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades. Despite our best effort, there is still a significant amount of patients who remain symptomatic and/or experiences progressive joint damage and disability. Regardless of the cause, either its lack of compliance or poor tolerability, more effective treatments are needed.